Safety of Anal Curcumin

Phase 1 Recruiting 48 enrolled Lisa Flowers

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgical excision (cutting out the abnormal cells)), which have potential short- and long-term side effects.

Timeline

Start: 2025-03-17
Primary completion: 2026-07
Completion: 2026-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Curcumin	Small molecule	500 mg	Other
Subject	Curcumin	Small molecule	1000 mg	Other
Subject	Curcumin	Small molecule	1500 mg	Other
Subject	Curcumin	Small molecule	2000 mg	Other
Subject	Curcumin	Small molecule	2500 mg	Other
Subject	Curcumin	Small molecule	3000 mg	Other
Subject	Curcumin	Small molecule	3500 mg	Other
Subject	Curcumin	Small molecule	4000 mg	Other

Safety of Anal Curcumin

Summary

Timeline

Drugs

Indications